Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

garysnoop1 348 posts  |  Last Activity: May 28, 2016 8:04 AM Member since: Oct 16, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • novio Pharmaceuticals, Inc. (Nasdaq: INO) announced that its Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its fully enrolled phase I study of 75 healthy subjects. Detailed immunogenicity and safety data is being prepared for peer-reviewed publication. In previously reported preclinical testing in mice and non-human primates, the Ebola vaccine protected 100% of immunized animals from sickness and death following exposure to a lethal dose of Ebola virus.

    This human study (CT.gov: NCT02464670) was conducted by an Inovio-led consortium, which was selected and awarded $45 million by the U.S. Defense Advanced Research Projects Agency (DARPA) in 2015 to take a multi-faceted approach to prevent and treat Ebola infection.

    This initial trial evaluated INO-4212 in five groups of healthy subjects. INO-4212 consists of two optimized SynCon® DNA plasmids coding for the Ebola glycoprotein antigen from circulating Ebola strains from 1975 - 2014. These plasmids were tested separately and together in muscle and skin in five study arms, one including Inovio’s DNA-based IL-12 immune activator. Of 69 evaluated subjects, 64 (92.7%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 48 subjects (69.6%) seroconverted after only two doses.

    Significantly, in the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations. Similarly, in the study arm receiving the vaccine with intramuscular administration in combination with plasmid IL-12, 12 of 13 evaluable subjects (92.3%) demonstrated strong antibody responses after only two immunizations and 13 of 13 (100%) produced strong antibody responses after three immunizations.

    The Ebola glycoprotein specific geometric mean antibody titers measured in the five cohorts ranged from over 2,000 to greater than 46,000. Significantly, a majority of vaccinated subjects in each of the five cohorts produced strong Ebola antigen specific T-cell responses as measured by interferon gamma ELISpot analysis.

    To date INO-4212 has been well tolerated and has not demonstrated systemic serious adverse effects, such as fever, joint pain, and low white blood cell counts, reported in association with some viral vector based Ebola vaccines currently in development. Moreover, unlike the viral vectored vaccines which must be kept frozen, INO-4212 was formulated in a solution which was kept refrigerated (2-8 C).


    A Message from Citizens Bank
    Conquer your student loans.
    What's your plan for paying off your student loans? 90% of those who've refinanced with us would recommend it. Get ahead of your debt. Calculate how much you could save.
    See More
    The data was presented today by Dr. Niranjan Y. Sardesai, Inovio’s Chief Operating Officer and Principal Investigator on the DARPA Ebola program, at The World Vaccine Congress in Washington, DC. Dr. Sardesai said, “The induction of strong Ebola specific antibody and T cell responses has been difficult to achieve in previous human studies. We are pleased by the immune responses achieved using two and three vaccination regimens in humans with our optimized DNA vaccines delivered using electroporation, adding to the successful animal immune response and challenge studies using our approach. We are particularly excited about the positive immunology data using intradermal immunization as this delivery would facilitate even greater clinical and commercial potential for DNA vaccination.”

    “These initial data from our Ebola DNA vaccine represent just a first step in this DARPA-funded program. We look forward to rapidly moving this DNA vaccine into larger human studies on the path to product licensure. We are also advancing our Ebola dMAb™ product and expect to clinically test that independently of the DNA vaccine approach,” said Dr. J. Joseph Kim, President and CEO.

    Under the DARPA-funded program Inovio and its collaborators are developing multiple approaches against Ebola. This program allows for the development and early clinical testing of:

    1) Inovio's DNA-based vaccine against Ebola

    2) Inovio's therapeutic Ebola dMAb™ product. This new technology has properties best suited to respond to an Ebola outbreak in that the product could be manufactured expediently on a large scale using proven fermentation technology, is thermal-stable, and may provide more rapid therapeutic benefit (as shown in Inovio’s Chikungunya and dengue programs);

  • Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments. The study will enroll patients who are in the early stages of chronic HCV infection to determine the therapy’s ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability. In this dose-escalation study INO-8000 will be combined with increasing doses of DNA-based IL-12 (INO-9012), an immune activator, which in previous studies has been shown to increase the therapeutic immune response to DNA immunotherapies.

    The study is funded by the National Cancer Institute’s Division of Cancer Prevention and will be conducted at the Mayo Clinic and other U.S. sites.

    Among those initially infected with HCV, 75 to 85 percent will go on to develop chronic illness. More than 170 million people around the world are chronically infected with HCV. According to the U.S. Centers for Disease Control (CDC) an estimated 3.5 million people in the US are chronically infected with HCV, with about 20,000 new cases of chronic HCV reported in the US in the last year. About 15,000 people in the US die each year of HCV-related causes.

    Inovio's SynCon® DNA immunotherapy, INO-8000, is encoded for the antigens NS3/4A, NS4B, and NS5A of HCV genotypes 1a and 1b, the most difficult-to-treat genotypes. The product is designed to induce robust T cells to eliminate cells displaying these antigens and has been shown in published preclinical studies to generate powerful HCV-specific T cell responses throughout the body and in the liver.

    Dr. Jeffrey Jacobson, the study’s Principal Investigator, said “Development of a vaccine therapy against hepatitis C would be important as a less expensive, simpler treatment alternative to several months of medication that should encourage better patient compliance, particularly in difficult-to-treat patient populations. It also holds the promise of inducing immunity protective against re-infection in patients who continue to be exposed, a not uncommon problem.” Dr. Jacobson is Professor of Medicine, Neuroscience and Neurovirology at the Lewis Katz School of Medicine, Temple University.

    Dr. J. Joseph Kim, President and CEO, said, “Despite recent treatment advances, HCV infection remains a burden on our healthcare and payor system and continues to spread. Today’s expensive drugs are highly effective in treating HCV but are not available to the majority of infected individuals. We are pleased to join the NCI and Mayo Clinic in this quest to develop an alternative medical solution to fight this disease, which remains one of the fastest-developing markets in healthcare."

    Inovio previously announced that it signed a collaborative agreement with GeneOne Life Sciences to develop INO-8000, along with a DNA IL-28 immune activator, in drug-resistant HCV patients in a phase I study in Korea. That study is on-going.

  • Watch the run..prof that we are in the running andcalms my nerves

  • Shorts your being set up..get a good night's sleep..

  • Morton Collins Insider Buy
    Shares block amounting to exactly $650,925 U.S. Dollars was reported in a document submitted to the Washington-based Security and Exchange Commission on April 18, 2016. According to which, Morton Collins, the director of Inovio Pharmaceuticals Inc also an insider of the Pinksheet-listed company had purchased a total of 68,400 shares [Bold1 ] – ( at $9.5 for each one share ). In the last month, he also acquired shares with a total value $ USD. Obviously, the trade gained attention, as Mr. Morton currently has rights to 303,091 shares, accounting for 0.41% of the Company’s market cap.

    Out of 5 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. $31 is the highest target while $13 is the lowest. The $18.6 average target is 111.06% above today’s ($9.95) stock price. Inovio Pharmaceuticals was the topic in 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Brean Capital maintained the stock on March 14 with “Buy” rating. Zacks downgraded the shares of INO in a report on August 14 to “Hold” rating.

    The institutional sentiment increased to Infinity in Q4 2015. Its up Infinity, from 0.5 in 2015Q3. The ratio increased, as 0 funds sold all Inovio Pharmaceuticals Inc shares owned while 0 reduced positions. 1 funds bought stakes while 1 increased positions. They now own 185,610 shares or 227.33% more from 56,705 shares in 2015Q3.

    Neville Rodie & Shaw Inc holds 0.03% of its portfolio in Inovio Pharmaceuticals Inc for 10,000 shares. Alerus Investment Advisors Corp owns 1,600 shares or 0.01% of their US portfolio. Moreover, Ameriprise Financial Inc has 0% invested in the company for 49,254 shares. The New York-based Estabrook Capital Management has invested 0% in the stock. Parametric Portfolio Associates Llc, a Washington-based fund reported 30,651 shares.

    About 883,135 shares traded hands. Inovio Pharmaceuticals Inc (NASDAQ:INO) has risen 33.47% since September 10, 2015 and is uptrending. It has outperformed by 26.90% the S&P500.

    Inovio Pharmaceuticals, Inc. is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has a market cap of $715.54 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus.

    According to Zacks Investment Research, “Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company’s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio’s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company’s partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania

  • Wall Street now thinks shares of tiny biotech Inovio Pharmaceuticals (NASDAQ:INO) have a potential upside of 232%.

    According to data from S&P Capital IQ, Wall Street now thinks shares of tiny biotech Inovio Pharmaceuticals (NASDAQ:INO) have a potential upside of 232%. This small, clinical-stage biotech develops DNA-based immunotherapies and vaccines for cancers and infectious diseases.

    Analysts covering this stock seem impressed by Inovio's emerging clinical pipeline, which is led by its late-stage asset VGX-3100, an immunotherapy targeting the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells. The biotech's pipeline also sports several experimental therapies being co-developed with Big Pharma partners AstraZeneca (NYSE:AZN) and Roche:
    Perhaps the first thing investors need to understand is that Inovio is essentially the elder statesman within its immediate peer group. At present, the landscape of clinical-stage biopharmas and biotechs is filled mostly with relatively new companies, many of which were only founded in the last five years during the great biotech bull run of 2010 to 2015.

    By contrast, Inovio was originally founded in 1979 and incorporated in 1983, and it's still searching for its first FDA-approved product.

    With Inovio now barreling toward the start of a pivotal late-stage study for VGX-3100, however, I think it's high time to consider whether this long-lived company is finally coming of age. The answer to this question seems to lie in VGX-3100's chances of successfully completing its planned late-stage study. So let's turn our attention to the published clinical data.

    Cancer Research
    Image source: Cancer Institute of Columbia.

    According to an article recently published in The Lancet, the modified intention-to-treat analysis produced a histopathological regression rate of 48.2% (55 out of 114) in the VGX-3100 arm, compared to a rate of 30% (12 out of 40) among patients receiving a placebo. This comparison was statistically significant with a p-value of 0.034.

  • Inovio, based in Plymouth Meeting, Pennsylvania, said Wednesday it would ask US regulatory authorities to accelerate the process for approving the vaccine with an eye towards marketing the medicine as quickly as possible.The World Health Organization (WHO) declared the Zika outbreak an international health emergency on February 1 and said infections were reported in more than two dozen countries in South and Central America and the Caribbean, with Brazil the hardest hit.

  • Dr. Weiner was co-founder with J. Joseph Kim, Ph.D., Inovio’s CEO, of VGX Pharmaceuticals in 2000; via merger VGX later became Inovio Pharmaceuticals. Dr. Weiner will continue to serve as Chair of the company’s Scientific Advisory Board, a position he has held since the formation of the company in 2000.
    Dr. J.Kim, Inovio's President and CEO, said, "Innovation is central to our company and its potential. While our board has deep expertise in corporate development and product commercialization, a strategic perspective on key scientific and competitive trends is important to guide critical corporate strategy and investment decisions.Dr. Weiners knowledge and judgment will be invaluable to Inovio as we continue to advance differentiated immunotherapy technology to become valuable medicines.I cant wait to see what comes out of this as we progress.

    Sentiment: Strong Buy

  • Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has reserved a top momentum style rating from Zacks Research. The momentum rating acts as an important barometer to show as to when a stock will attain a favourable position, which will provide a window of opportunity to benefit from equity movement in either direction. Momentum traders often study the price swings of a stock and draw opinion that the stock will move in a particular direction, yielding a profitable trade. The momentum strategy aims to provide a short-term forecast about the stock price movements over fundamental stock analysis and is being taken into account by experienced traders only

  • Thyey have a little better finger on the pulse here?why would they be steping in here when all thier is, is potential? maybe they know this potential is about to solidify...They dont usually make bad moves..

  • According to data from S&P Capital IQ, Wall Street now thinks shares of tiny biotech Inovio Pharmaceuticals (NASDAQ:INO) have a potential upside of 232%. This small, clinical-stage biotech develops DNA-based immunotherapies and vaccines for cancers and infectious diseases.

    Analysts covering this stock seem impressed by Inovio's emerging clinical pipeline, which is led by its late-stage asset VGX-3100, an immunotherapy targeting the E6 and E7 antigens of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells. The biotech's pipeline also sports several experimental therapies being co-developed with Big Pharma partners AstraZeneca (NYSE:AZN) and Roche:
    Perhaps the first thing investors need to understand is that Inovio is essentially the elder statesman within its immediate peer group. At present, the landscape of clinical-stage biopharmas and biotechs is filled mostly with relatively new companies, many of which were only founded in the last five years during the great biotech bull run of 2010 to 2015.

    By contrast, Inovio was originally founded in 1979 and incorporated in 1983, and it's still searching for its first FDA-approved product.

    With Inovio now barreling toward the start of a pivotal late-stage study for VGX-3100, however, I think it's high time to consider whether this long-lived company is finally coming of age. The answer to this question seems to lie in VGX-3100's chances of successfully completing its planned late-stage study. So let's turn our attention to the published clinical data.

    Cancer Research
    Image source: Cancer Institute of Columbia.

    According to an article recently published in The Lancet, the modified intention-to-treat analysis produced a histopathological regression rate of 48.2% (55 out of 114) in the VGX-3100 arm, compared to a rate of 30% (12 out of 40) among patients receiving a placebo. This comparison was statistically significant with a p-value of 0.034.

    Although this significant result appears prom

  • How far off can they be..get in now..Barclays..135.00 ..

    Sentiment: Strong Buy

  • garysnoop1 by garysnoop1 Mar 10, 2016 4:17 PM Flag

    Covering sell-side analysts have given Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares an average rating of 1. This number provided by Zacks Research takes into account 5 analysts who have provided stock recommendations. Using a 1 to 5 scale, a 1 or 2 rating would signify a Buy recommendation, and a 4 or a 5 would signify a Sell recommendation. A rating of 3 would signify a Hold recommendation. In addition to the average broker rating we can take a look at where the analysts see the stock headed near term. In the sell-side reports provided to institutions, the research firms typically offer a projected price target on the stock. The time frame and criteria can differ depending on the firm, so to get a general feel for where they see the stock heading, we look at the consensus number. Based on the 5 providing stock targets, the highest stands at $31 and the lowest at $14. The mean, or consensus number is $20.2.

  • Oh, and all the profit we've made so far...it's a trick.Stay short,I'll tell you when to cover..Gary loves you..

    Sentiment: Strong Buy

  • I am surprised that no larger corporation has bought Inovio yet. The price would be cheap compared to the potential.

    Gilead Sciences (NASDAQ:GILD) would be my number one pick, if I were allowed to make a match. Gilead has been most successful with its HIV and HCV programs. By adding Inovio's DNA vaccine approach it is possible Gilead could cure HIV, though Gilead is already pursuing other approaches to a cure. More strategically, Gilead needs a next-big-growth area to excite investors. That would probably be an extension of its cancer program. By adding Inovio's DNA vaccines to other cancer therapies Gilead could do for cancer what it has done for HCV.

    Other possible acquirers would be Merck and GlaxoSmithKline (NYSE:GSK), but almost any large company involved with viral therapies or cancer therapies could benefit from the acquisition. Even companies specializing in monoclonal antibodies might want to procure Inovio's DNA-based antibody technology (DMAB). If MedImmune likes what it sees in the INO-3112, it might make sense to buy all of Inovio rather than making milestone payments and paying royalties for the single therapy.

    As a long-term investor, I would prefer that Inovio remain a stand-alone company. If its HPV vaccine, or any of its many earlier stage vaccines, became a commercial success, if would be far more valuable than what it would get in a buyout situation today. I would rather be patient, even if that means waiting 2 to 5 years, and get the full value of owning a major biotech company that I bought back when it was a micro-cap play.

  • Reply to

    Inovio mentioned first onTV on CNBC Milisa Lee

    by garysnoop1 May 20, 2016 12:36 PM
    garysnoop1 garysnoop1 May 20, 2016 12:40 PM Flag

    Only that we were working on a vaccine,we were the first words out of her mouth..We are known..

  • garysnoop1 by garysnoop1 Feb 29, 2016 11:19 AM Flag

    What's important is that we base out here.It's usually a rule of thumb, the longer the base, the higher the run. Keep that in mind pro traders use that as a rule for the most part.Shorts eventually look at that as a bad sign,at least the smart omes do..SSB

  • I believe this purchase is to put some time between the purchase and some real good news that might be comming down the road..Wouldn't show insider knowledge with a nice time frame in between said purchase...That kind of volume purchase wasn't done for nothing..now..bring the news..SSB

    Sentiment: Strong Buy

  • PLYMOUTH MEETING (CBS) — Officials at a Plymouth Meeting pharmaceutical company say they lead the world in the race to get a Zika virus vaccine to market. They got a visit from Congressman Brendan Boyle as their research continues.

    Inovio Pharmaceuticals uses a DNA based platform to create vaccines. Much faster than the traditional method of using components of the actual virus, says founder and CEO J. Joseph Kim. He says Inovio this is the first to design and make the Zika vaccine, and the first to test it in animals.

    “And we’ll be the first to manufacture the clinical product for Zika and later this year we’ll be the first into human testing,” Kim said.

    Congressman Brendan Boyle met with Dr. Kim to discuss ways the federal government could help the process.

    “If we put a little more forethought into these things we can be more effective and save a lot of money in the long run if we properly fund this research initially rather than waiting for an outbreak to happen,” he said.

    Another advantage, researchers say, since DNA-based vaccines don’t use any virus, they could potentially be safer for pregnant women..from fb thanks jim..M..SSB

  • Reply to

    Big Zika and MERS News Coming

    by patcarr832 Mar 31, 2016 10:59 AM
    garysnoop1 garysnoop1 Mar 31, 2016 6:07 PM Flag

    I talked to them at length after hrs..You can bet on it. pay attention to the recient moves thev'e made..Also 160 mil. in cash ,good thru 2018...Buy then,money won't be the problem.The 3rd and 4th qtr. will take care of that nicely.The recent move Dr. Weiner made is the tell.

    Sentiment: Strong Buy

CVM
0.5050.000(0.00%)May 27 4:02 PMEDT